EGFR and neoplasm: The first one (NCT05341492) is evaluating the safety and efficacy of EGFR/B7H3 CAR-T cell therapy in EGFR/B7H3-positive advanced solid cancers (including TNBC), and the second one is testing the anti-tumor activities and safety profiles of CAR-EGFR-TGFβR-KO T cell therapy in previously treated advanced EGFR positive solid tumors (including TNBC) However, no results regarding TNBC patients have yet been officially reported